Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: Implications for progression of Parkinson's disease

European Journal of Neuroscience

Volumn 32, Issue 10, 2010, Pages 1695-1706

  Villar Cheda, Begoña ^a,b   Rodríguez Pallares, Jannette ^a,b   Valenzuela, Rita ^a,b   Muñoz, Ana ^a,b   Guerra, Maria J ^a,b   Baltatu, Ovidiu C ^c,d   Labandeira Garcia, Jose L ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Angiotensin; Dopamine; Neuroinflammation; Neuroprotection; Parkinson's disease

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CELL ANTIGEN; COMPLEMENTARY RNA; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; NEURON SPECIFIC NUCLEAR PROTEIN; OX42 ANTIGEN; OXIDOPAMINE; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; CONCENTRATION RESPONSE; DENERVATION; DISEASE COURSE; DOWN REGULATION; IMMUNOREACTIVITY; MALE; MESENCEPHALON; MICROGLIA; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; REGULATORY MECHANISM;

ADRENERGIC UPTAKE INHIBITORS; ANGIOTENSIN II; ANIMALS; CORPUS STRIATUM; DISEASE PROGRESSION; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; RESERPINE; SUBSTANTIA NIGRA;

EID: 78349241045     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2010.07448.x     Document Type: Article

References (48)

1. Allen, A.M., MacGregor, D.P., Chai, S.Y., Donnan, G.A., Kaczymarzyk, S., Richardson, K., Kalnins, R., Ireton, J. & Mendelsohn, F.A.O. (1992) Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol., 32, 339-344.
2. Babior, B. (1999) NADPH oxidase: An update. Blood, 93, 1464-1476.
3. Babior, B.M. (2004) NADPH oxidase. Curr. Opin. Immunol., 16, 42-47.
4. Benigni, A., Corna, D., Zoja, C., Sonzogni, A., Latini, R., Salio, M., Conti, S., Rottoli, D., Longaretti, L., Cassis, P., Morigi, M., Coffman, T.M. & Remuzzi, G. (2009) Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest., 119, 524-530.
5. Brown, D.C., Steward, L.J., Ge, J. & Barnes, N.M. (1996) Ability of angiotensin II to modulate striatal dopamine release via AT1 receptor in vitro and in vivo. British J. Pharmacol., 18, 414-420.
6. Cai, H., Griendling, K.K. & Harrison, D.G. (2003) The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci., 24, 471-478.
7. Chabrashvili, T., Kitiyakara, C., Blau, J., Karber, A., Islam, S., Welch, W.J. & Wilcox, C.F. (2003) Effect of Ang II type 1 and 2 receptors on oxidative stress, renal NAD(P)H oxidase, and SOD expression. Am. J. Physiol. Regu. Integr. Comp. Physiol., 285, R117-R124.
8. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C. & Marek, K. (2004) Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med., 351, 2498-2508.
9. Färber, K., Pannasch, U. & Kettenmann, H. (2005) Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell. Neurosci., 29, 128-138.
10. Ferrari, R., Guardigli, G., Cicchitelli, G., Valgimigli, M., Merli, E., Soukhomorskaia, O. & Ceconi, C. (2002) Angiotensin II overproduction: enemy of the vessel wall. Eur. Heart J., 4(Suppl A), A26-A30.
11. Gelband, C.H., Zhu, M., Lu, D., Reagan, L.P., Fluharty, S.J., Posner, P., Raizada, M.K. & Sumners, C. (1997) Functional interactions between neuronal AT1 and AT2 receptors. Endocrinology, 138, 2195-2198.
12. Gildea, J.J. (2009) Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr. Opin. Nephrol. Hypertens., 18, 28-32.
13. Hudson, J.L., Van Horne, C.G., Stromberg, I., Brock, S., Clayton, J., Masserano, J., Hoffer, B.J. & Gerhardt, G.A. (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res., 626, 167-174.
14. Hussain, T., Abdul-Wahab, R., Kotak, D.K. & Lokhandwala, M.F. (1998) Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules. Hypertension, 32, 1054-1059.
15. Joglar, B., Rodriguez-Pallares, J., Rodríguez-Perez, A.I., Rey, P., Guerra, M.J. & Labandeira-Garcia, J.L. (2009) The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem., 109, 656-669.
16. Kannari, K., Tanaka, H., Maeda, T., Tomiyama, M., Suda, T. & Matsunaga, M. (2000) Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. J. Neurochem., 74, 263-269.
17. Khan, F., Spicarová, Z., Zelenin, S., Holtbäck, U., Scott, L. & Aperia, A. (2008) Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am. J. Physiol. Renal Physiol., 295, F1110-F1116.
18. Labandeira-Garcia, J.L., Rozas, G., Lopez-Martin, E., Liste, I. & Guerra, M.J. (1996) Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression. Exp. Brain. Res., 108, 69-84.
19. Li, M. & Shah, A.M. (2003) Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J. Biol. Chem., 278, 12094-12100.
20. Li, H., Armando, I., Yu, P., Escano, C., Mueller, S.C., Asico, L., Pascua, A., Lu, Q., Wang, X., Villar, V.A., Jones, J.E., Wang, Z., Periasamy, A., Lau, Y.S., Soares-da-Silva, P., Creswell, K., Guillemette, G., Sibley, D.R., Eisner, G., Gildea, J.J., Felder, R.A. & Jose, P.A. (2008) Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J. Clin. Invest., 118, 2180-2189.
21. Maul, B., Krause, W., Pankow, K., Becker, M., Gembardt, F., Alenina, N., Walther, T., Bader, M. & Siems, W.E. (2005) Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J., 19, 1474-1481.
22. Mendelsohn, F.A.O., Jenkins, T.A. & Berkovic, S.F. (1993) Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rat. Brain Res., 613, 221-229.
23. Miyazaki, I., Asanuma, M., Diaz-Corrales, F.J., Miyoshi, K. & Ogawa, N. (2004) Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res., 1029, 120-123.
24. Monti, J., Schinke, M., Böhm, M., Ganten, D., Bader, M. & Bricca, G. (2001) Glial angiotensinogen regulates brain angiotensin II receptors in transgenic rats TGR(ASrAOGEN). Am. J. Physiol. Regul. Integr. Comp. Physiol., 280, R233-R240.
25. Mytilineou, C., Walker, R.H., JnoBaptiste, R. & Olanow, C.W. (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther., 304, 792-800.
26. Phillips, M.I. & De Oliveira, E.M. (2008) Brain renin angiotensin in disease. J. Mol. Med., 86, 715-722.
27. Phillips, M.I. & Kagiyama, S. (2002) Angiotensin II as a pro-inflammatory mediator. Curr. Opin. Invest. Drugs, 3, 569-577.
28. Re, R.N. (2004) Tissue renin angiotensin systems. Med. Clin. North Am., 88, 19-38.
29. Rey, P., Lopez-Real, A., Sanchez-Iglesias, S., Muñoz, A., Soto-Otero, R. & Labandeira-Garcia, J.L. (2007) Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging, 28, 555-567.
30. Rodriguez-Pallares, J., Parga, J.A., Muñoz, A., Rey, P., Guerra, M.J. & Labandeira-Garcia, J.L. (2007) Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J. Neurochem., 103, 145-156.
31. Rodriguez-Pallares, J., Rey, P., Parga, J.A., Muñoz, A., Guerra, M.J. & Labandeira-Garcia, J.L. (2008) Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis., 31, 58-73.
32. Rueckschloss, U., Quinn, M.T., Holtz, J. & Morawietz, H. (2002) Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 22, 1845-1851.
33. Saavedra, J.M. (2005) Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell. Mol. Neurobiol., 25, 485-512.
34. Scheller, D., Chan, P., Li, Q., Wu, T., Zhang, R., Guan, L., Ravenscroft, P., Guigoni, C., Crossman, A.R., Hill, M. & Bezard, E. (2007) Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp. Neurol., 203, 415-422.
35. Schinke, M., Baltatu, O., Böhm, M., Peters, J., Rascher, W., Bricca, G., Lippoldt, A., Ganten, D. & Bader, M. (1999) Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. Proc. Natl. Acad. Sci. USA, 96, 3975-3980.
36. Sechi, L.A., Griffin, C.A., Giacchetti, G., Valentin, J.P., Llorens-Cortes, C., Corvol, P. & Schambelan, M. (1996) Tissue-specific regulation of type 1 angiotensin II receptor mRNA levels in the rat. Hypertension, 28, 403-408.
37. Seshiah, P.N., Weber, D.S., Rocic, P., Valppu, L., Taniyama, Y. & Griendling, K.K. (2002) Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res., 91, 406-413.
38. Sugaya, T., Nishimatsu, S., Tanimoto, K., Takimoto, E., Yamagishi, T., Imamura, K., Goto, S., Imaizumi, K., Hisada, Y., Otsuka, A., Uchida, U., Sugiura, M., Fukamizu, A. & Murakami, K. (1995) Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem., 270, 18719-18722.
39. Touyz, R.M., Chen, X., Tabet, F., Yao, G., He, G., Quinn, M.T., Pagano, P.J. & Schiffrin, E.L. (2002) Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res., 14, 1205-1213.
40. Trugman, J.M. & James, C.L. (1992) Rapid development of dopaminergic supersensitivity in reserpine-treated rats demonstrated with 14C-2-deoxyglucose autoradiography. J. Neurosci., 12, 2875-2879.
41. Wang, G., Anrather, J., Huang, J., Speth, R.C., Pickel, V. & Iadecola, C. (2004) NADPH oxidase contributes to angiotensin II signalling in the nucleus tractus solitarius. J. Neurosci., 24, 5516-5524.
42. 2+, and protein kinase C play a role in angiotensin II-induced free radical production in nucleus tractus solitarius. Hypertension, 48, 482-489.
43. Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.K., Ischiropoulos, H. & Przedborski, S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci., 22, 1763-1771.
44. Wu, D., Teisman, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H. & Przedborski, S. (2003a) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc. Natl Acad. Sci. USA, 100, 6145-6150.
45. Wu, Z., Zheng, W. & Sandberg, K. (2003b) Estrogen regulates adrenal angiotensin type 1 receptors by modulating adrenal angiotensin levels. Endocrinology, 144, 1350-1356.
46. Zeng, C., Liu, Y., Wang, Z., He, D., Huang, L., Yu, P., Zheng, S., Jones, J.E., Asico, L.D., Hopfer, U., Eisner, G.M., Felder, R.A. & Jose, P.A. (2006) Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ. Res., 99, 494-500.
47. Zeng, C., Zhang, M., Asico, L.D., Eisner, G.M. & Jose, P.A. (2007) The dopaminergic system in hypertension. Clin. Sci. (Lond), 112, 583-597.
48. Zhang, G.X., Lu, X.M., Kimura, S. & Nishiyama, A. (2007) Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc. Res., 76, 204-212.